JP2001513629A - ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 - Google Patents
ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質Info
- Publication number
- JP2001513629A JP2001513629A JP53641598A JP53641598A JP2001513629A JP 2001513629 A JP2001513629 A JP 2001513629A JP 53641598 A JP53641598 A JP 53641598A JP 53641598 A JP53641598 A JP 53641598A JP 2001513629 A JP2001513629 A JP 2001513629A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- chemokine
- chemokines
- fragment
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. A41Lタンパク質またはそのケモカイン結合フラグメントの有効量を、 医薬として許容される担体とともに含有する医薬。 2. A41Lタンパク質またはフラグメントが抗炎症薬として存在している請 求の範囲1に記載の医薬。 3. 前記抗炎症薬が、CXCグループ由来の少なくとも1種のケモカインに結 合できる請求の範囲2に記載の医薬。 4. 前記抗炎症薬が、ケモカインのMigまたはIP−10などの少なくとも 1種のIFN−γ誘発ケモカインに結合できる請求の範囲3に記載の医薬。 5. 前記抗炎症薬が、単一または複数のケモカインの活性を阻害する請求の範 囲3または4に記載の医薬。 6. MigおよびIP−10などのIFN−γ誘発ケモカイン類が仲介する症 状を治療または予防するための、請求の範囲2−5のいずれか一つに記載の医薬 。 7. A41Lタンパク質またはフラグメントが抗ウイルス薬として存在してい る請求の範囲1に記載の医薬。 8. 細胞のケモカイン受容体を介して標的細胞への感染を仲介する病原体によ る感染を治療または予防するための請求の範囲7に記載の医薬。 9. 前記ケモカイン受容体がCXCR3などのCXCケモカインの受容体であ る請求の範囲8に記載の医薬。 10.細胞標的へのHIVの結合および/または感染を阻害するための請求の範 囲7−9のいずれか一つに記載の医薬。 11.予防に使用するための請求の範囲7−10のいずれか一つに記載の医薬。 12.A41Lが、ワクシニアウイルスA41LなどのポックスウイルスA41 Lである請求の範囲1−11のいずれか一つに記載の医薬。 13.A41Lタンパク質またはそのフラグメントが組換えタンパク質またはそ のフラグメントである請求の範囲1−12のいずれか一つに記載の医薬。 14.天然のA41Lタンパク質を発現できないように遺伝子工学で処理されて いる組換えポックスウイルス。 15.ケモカイン結合A41Lタンパク質を発現できない請求の範囲14に記載 の組換えポックスウイルス。 16.遺伝子工学で処理されたワクシニアウイルスである請求の範囲14または 15に記載の組換えポックスウイルス。 17.治療または予防に用いるため医薬として許容される担体とともに、請求の 範囲14−16のいずれか一つに記載の組換えポックスウイルスを含有する医薬 。 18.下記ステップを含んでなる検出方法: a)A41Lタンパク質またはそのケモカイン結合フラグメントであるケモカ イン結合分子を準備し; b)そのケモカイン結合分子を試料と接触させ; c)そのケモカイン結合分子と、試料中のケモカインとの相互作用を検出する 。 19.生物試料中に1種以上のケモカインが存在しているのを検出するための請 求の範囲18に記載の検出方法。 20.CXCグループのケモカイン類のなかの1種以上のケモカインを検出する 請求の範囲18または19に記載の検出方法。 21.MigまたはIP−10などの少なくとも1種のIFN−γ誘発ケモカイ ンを検出するための請求の範囲18−20のいずれか一つに記載の検出方法。 22.ケモカイン結合分子が固体支持体上に固定されている請求の範囲18−2 1のいずれか一つに記載の検出方法。 23.試料中の1種以上のケモカインの活性を阻害する方法であって;試料を、 A41Lタンパク質またはそのケモカイン結合フラグメントであるケモカイン結 合分子の有効量と接触させることを含んでなる方法。 24.請求の範囲1−23のいずれか一つに記載の方法または医薬に使用するた めの、精製されたA41Lタンパク質またはそのケモカイン結合フラグメント。 25.請求の範囲24に記載の精製されたA41Lタンパク質またはフラグメン トを含んでなるキット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9703592.7A GB9703592D0 (en) | 1997-02-21 | 1997-02-21 | Poxvirus chemokine-binding protein |
GBGB9800113.4A GB9800113D0 (en) | 1998-01-05 | 1998-01-05 | A soluble vaccinia virus protein that binds chemokines |
GB9800113.4 | 1998-01-05 | ||
GB9703592.7 | 1998-01-05 | ||
PCT/GB1998/000569 WO1998037217A1 (en) | 1997-02-21 | 1998-02-23 | A soluble vaccinia virus protein that binds chemokines |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001513629A true JP2001513629A (ja) | 2001-09-04 |
JP2001513629A5 JP2001513629A5 (ja) | 2004-12-09 |
JP4191255B2 JP4191255B2 (ja) | 2008-12-03 |
Family
ID=26311039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53641598A Expired - Fee Related JP4191255B2 (ja) | 1997-02-21 | 1998-02-23 | ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 |
Country Status (7)
Country | Link |
---|---|
US (3) | US6355252B1 (ja) |
EP (2) | EP0985046B1 (ja) |
JP (1) | JP4191255B2 (ja) |
AT (1) | ATE323170T1 (ja) |
AU (1) | AU749921B2 (ja) |
DE (1) | DE69834179T2 (ja) |
WO (1) | WO1998037217A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005502723A (ja) * | 2001-09-20 | 2005-01-27 | シェーリング コーポレイション | 免疫応答のアジュバントとしてのケモカイン |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0985046B1 (en) * | 1997-02-21 | 2006-04-12 | Oxxon Therapeutics Limited | Recombinant poxvirus incapable of expressing a41l gene, coding for a soluble protein that binds chemokines |
GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
WO2002080948A1 (en) * | 2001-04-05 | 2002-10-17 | The Trustees Of Princeton University | Compositions and methods for treating inflammation and related conditions |
WO2003005953A2 (en) * | 2001-07-12 | 2003-01-23 | Immunex Corporation | Viral proteins capable of binding lar |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
AU2003259117A1 (en) * | 2002-07-10 | 2004-01-23 | The Regents Of The University Of California | Antimicrobial activity of interferon-inducible elr chemokines |
EP2044948B1 (en) * | 2002-08-12 | 2013-10-30 | Jennerex Biotherapeutics ULC | Vaccinia viruses for use in treating cancer |
WO2005017208A1 (en) * | 2003-07-31 | 2005-02-24 | George Mason Intellectual Properties, Inc. | Compositions and methods for treating or preventing hiv infection |
US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
US20070160571A1 (en) * | 2006-01-11 | 2007-07-12 | Mitchell Krathwohl | Composition and method for inducing protective vaccine response |
WO2006076383A2 (en) * | 2005-01-11 | 2006-07-20 | Rosetta Stone Labs, Llc | Composition and method for inducing a protective vaccine response |
CA2621982C (en) * | 2005-09-07 | 2017-11-28 | Jennerex Biotherapeutics Ulc | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
CA2622772A1 (en) * | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
ATE485517T1 (de) | 2006-03-22 | 2010-11-15 | Viral Logic Systems Technology | Verfahren zur identifizierung von polypeptid- targets |
WO2008096359A2 (en) * | 2007-02-08 | 2008-08-14 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of multiple sclerosis and methods of using same |
KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
WO2008149354A2 (en) | 2007-06-04 | 2008-12-11 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of inflammatory diseases and methods of using same |
WO2009082594A2 (en) * | 2007-11-26 | 2009-07-02 | Fox Chase Cancer Center | Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents |
WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
ES2848650T3 (es) | 2009-09-14 | 2021-08-11 | Sillajen Biotherapeutics Inc | Terapia combinada contra el cáncer con virus vaccinia oncolítico |
JP6121910B2 (ja) | 2011-01-04 | 2017-04-26 | シラジェン バイオセラピューティクス インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69628838T2 (de) * | 1995-04-19 | 2004-05-06 | The John P. Robarts Research Institute, London | Chemokin bindendes protein und verfahren zu seiner verwendung |
US6140064A (en) * | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
WO1998036766A1 (en) * | 1997-02-21 | 1998-08-27 | Isis Innovation Limited | Anti-hiv protein |
EP0985046B1 (en) * | 1997-02-21 | 2006-04-12 | Oxxon Therapeutics Limited | Recombinant poxvirus incapable of expressing a41l gene, coding for a soluble protein that binds chemokines |
JP2001168323A (ja) * | 1999-12-06 | 2001-06-22 | Mitsubishi Electric Corp | 半導体装置の製造方法 |
-
1998
- 1998-02-23 EP EP98907032A patent/EP0985046B1/en not_active Expired - Lifetime
- 1998-02-23 US US09/367,781 patent/US6355252B1/en not_active Expired - Fee Related
- 1998-02-23 AT AT98907032T patent/ATE323170T1/de not_active IP Right Cessation
- 1998-02-23 EP EP20030022117 patent/EP1405916A1/en not_active Withdrawn
- 1998-02-23 AU AU63020/98A patent/AU749921B2/en not_active Ceased
- 1998-02-23 JP JP53641598A patent/JP4191255B2/ja not_active Expired - Fee Related
- 1998-02-23 WO PCT/GB1998/000569 patent/WO1998037217A1/en active IP Right Grant
- 1998-02-23 DE DE69834179T patent/DE69834179T2/de not_active Expired - Fee Related
-
2002
- 2002-01-15 US US10/047,761 patent/US20020071849A1/en active Pending
-
2004
- 2004-02-18 US US10/781,262 patent/US7384643B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005502723A (ja) * | 2001-09-20 | 2005-01-27 | シェーリング コーポレイション | 免疫応答のアジュバントとしてのケモカイン |
Also Published As
Publication number | Publication date |
---|---|
JP4191255B2 (ja) | 2008-12-03 |
WO1998037217A1 (en) | 1998-08-27 |
US7384643B2 (en) | 2008-06-10 |
EP1405916A1 (en) | 2004-04-07 |
US6355252B1 (en) | 2002-03-12 |
EP0985046A1 (en) | 2000-03-15 |
DE69834179D1 (de) | 2006-05-24 |
US20020071849A1 (en) | 2002-06-13 |
DE69834179T2 (de) | 2007-02-01 |
EP0985046B1 (en) | 2006-04-12 |
AU749921B2 (en) | 2002-07-04 |
ATE323170T1 (de) | 2006-04-15 |
US20040142002A1 (en) | 2004-07-22 |
AU6302098A (en) | 1998-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001513629A (ja) | ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 | |
Symons et al. | A study of the vaccinia virus interferon-γ receptor and its contribution to virus virulence | |
Alcamí et al. | Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus | |
Alcami et al. | A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection | |
Hutchens et al. | TLR3 increases disease morbidity and mortality from vaccinia infection | |
EP0840615B1 (en) | Chemokine binding protein and methods of use therefor | |
Vomaske et al. | Cytomegalovirus CC chemokine promotes immune cell migration | |
Xiang et al. | Identification of human and mouse homologs of the MC51L–53L–54L family of secreted glycoproteins encoded by the Molluscum contagiosum poxvirus | |
EP0555291A1 (en) | Vaccinia vectors, vaccinia genes and expression products thereof | |
JP2010077136A (ja) | 新規免疫修飾性タンパク質およびその有用な態様 | |
AU2002211744B2 (en) | Nucleic acid molecules and polypeptides for immune modulation | |
US20020098201A1 (en) | Novel myxoma genes for immune modulation | |
AU2002301315B2 (en) | A soluble vaccinia virus protein that binds chemokines | |
CA2383598A1 (en) | Therapeutic uses of m3 polypeptide | |
US7186408B2 (en) | Viral CD30 polypeptide | |
US20110288004A1 (en) | Viral Sequences and Uses Thereof | |
CN117164703A (zh) | 一种广谱中和SARS-CoV-2的中和抗体P5S-2B10及其应用 | |
CN116355081A (zh) | 一种广谱中和SARS-CoV-2的中和抗体P2-1D5及其应用 | |
AU754225B2 (en) | Chemokine binding protein and methods of use therefor | |
CN116120442A (zh) | 一种广谱中和SARS-CoV-2的中和抗体P2-1B1及其应用 | |
Totonchy et al. | Cytomegalovirus CC Chemokine Promotes Immune Cell Migration | |
JP2007130021A (ja) | ヒトgタンパク質ケモカインレセプターhdgnr10 | |
JP2000507090A (ja) | 免疫細胞サイトカイン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040316 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040316 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050722 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060822 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061101 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080902 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080918 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110926 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |